Blog | HemaCare

Ocrevus Lessens Pro-Inflammatory T-Cells in PPMS

Jun 15, 2021 10:15:00 AM / by Stacy Matthews Branch, DVM, PhD posted in B Cells, Autoimmune Disorders, Inflammation, T Cells


Ocrevus’s main immune cell target is B-cells, but a small study has shown that it can also lessen pro-inflammatory immune T-cells in patients with primary progressive multiple sclerosis.

Multiple Sclerosis (MS) is a chronic inflammatory, neurodegenerative, and demyelinating autoimmune disorder. The primary progressive form (PPMS) is characterized by a worsening of neurologic function with a gradual accumulation of disability from the onset of disease. The limited understanding of the pathogenesis of PPMS has hindered the development of reliable and effective treatments. However, there is an approved intravenous therapy, Ocrevus (ocrelizumab), a humanized monoclonal antibody developed by Genentech for treating patients with PPMS.

Read More

New Research Shows the Vital Role Metabolic Signaling Plays in Regulating Specialized T Cells

Jun 1, 2021 10:15:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Autoimmune Disorders, Cancer, T Cells


Scientists at St. Jude Children’s Research Hospital revealed that metabolic signaling mechanisms regulate the function of an eTreg cell.

Foxp3-expressing regulatory T cells are critical components of the immune system for the regulation of immune responses and the suppression of other immune cells for the maintenance of self-tolerance and regulation of immunity against pathogens and tumor cells.

Read More

Could Stem Cell Therapy Be the Better Treatment for MS?

May 12, 2020 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Autoimmune Disorders, Stem Cell Therapy, Stem Cells


A Phase III clinical trial comparing hematopoietic stem cell transplants to immunomodulators is underway.

Multiple sclerosis (MS) is an autoimmune disease characterized by the destruction of the myelin sheath of nerve fibers. There is no cure for the condition, but there are a number of FDA-approved immunomodulators or disease-modifying therapies to reduce relapses and slow disease progression. Despite the availability of these drugs, their varying efficacy, adverse effects, and expense are significant concerns. Therefore, a means to safely and effectively control MS symptoms and progression is still under investigation.

Read More

Finding Therapy for Sex-Biased Autoimmune Conditions

Apr 14, 2020 10:02:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Autoimmune Disorders, T Cells


By observing T cells, researchers are better identifying the connections between estrogen, testosterone, and autoimmune diseases.

The most common autoimmune diseases, such as rheumatoid arthritis, irritable bowel disease (IBD), and systemic lupus erythematous (SLE), affect women significantly more than men in terms of incidence, disease severity, progression, and response to therapy. Various studies have been conducted to explore the basis of the sexual dimorphism of autoimmune diseases. A prominent factor is the role of sex hormones in the sex-based differences associated with autoimmune diseases.

Read More

Is an Unusual Immune Cell the Cause of Type I Diabetes?

Sep 24, 2019 10:20:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Autoimmune Disorders, T Cells


Researchers at Johns Hopkins University and IBM Thomas J Watson Research Center discovered unique autoimmune cells in type 1 diabetes.

Over 30 million people living in the United States are affected by diabetes, and 5% of those have type 1 diabetes, an autoimmune disorder whereby the insulin-producing cells of the pancreas are destroyed by the body’s own immune system. This leads to a lack of sufficient insulin needed to assist the entry of glucose into cells, causing hyperglycemia. The mechanism of this aspect is mainly unknown. However, it is held that insulin is the target of the autoimmune attack that leads to type 1 diabetes.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts